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HIV can rapidly evolve when placed under selective
pressure, including immune surveillance or the
administration of antiretroviral drugs. Typically, a var-
iant protein allows HIV to directly evade the selective
pressure. Similarly, HIV has escaped suppression by
RNA interference (RNAi) directed against viral RNAs
by acquiring mutations at the target region that
circumvent RNAi-mediated inhibition while conserv-
ing necessary viral functions. However, when we
directed RNAi against the viral TAR hairpin, which
plays an indispensable role in viral transcription,
resistant strains were recovered, but none carried
a mutation at the target site. Instead, we isolated
several strains carrying promoter mutations that indi-
rectly compensated for the RNAi by upregulating
viral transcription. Combining RNAi with the applica-
tion of an antiviral drug blocked replication of such
mutants. Evolutionary tuning of viral transcriptional
regulation may serve as a general evasion mecha-
nism that may be targeted to improve the efficacy
of antiviral therapy.
INTRODUCTION
Human immunodeficiency virus (HIV) possesses a remarkable
ability to adapt and evade both host immune responses and
suppression by antiviral drugs. This capacity is driven by the
rapid genetic diversity that retroviruses acquire via reverse tran-
scription. During this process, HIV reverse transcriptase (RT)
introduces point mutations (0.2 errors per genome, per replica-
tion cycle) and recombines sequences from both parental RNA
strands by stochastically switching between RNA templates.
Since 1010–1012 new viruses may be produced per day in vivo,
HIV samples many possible genetic configurations, some of
which may imbue progeny viruses with selective advantages
(reviewed in Rambaut et al. [2004]).
Highly active antiretroviral therapy (HAART) has extended the
lives of HIV-positive patients; however, this approach suffers
many shortcomings. In particular, rapid retroviral mutation has
produced many drug-resistant strains of HIV (reviewed in Clavel
and Hance [2004]), and patient compliance is challenging, given484 Cell Host & Microbe 4, 484–494, November 13, 2008 ª2008 Elsethe drugs’ many side effects (reviewed in Carr [2003]). Conse-
quently, an urgent need exists for new HIV therapies that are
less prone to the generation of resistant viral strains.
An emerging and promising alternative to HAART is the thera-
peutic induction of RNA interference (RNAi), a highly conserved
cellular mechanism for suppressing gene expression. Briefly, the
cellular ribonuclease Dicer cleaves double-stranded RNAs or
short hairpin RNAs (shRNA) to create 21 nucleotide (nt) short
interfering RNA (siRNA) duplexes. The antisense strands of these
duplexes are used by the cellular RNA-induced silencing
complex (RISC) to sample a cell’s mRNAs and actively cleave
messages that are complementary to this guide strand (reviewed
in McManus and Sharp [2002]). Alternatively, guide strands
complementary to sequences within promoter regions have
been shown to downregulate gene expression through tran-
scriptional silencing (Castanotto et al., 2005). Thus, it is possible
to suppress HIV gene expression in a sequence-specific manner
using shRNAs targeting the viral genome.
HIV gag, pol, tat, rev, env, vif, and nef have been successfully
targeted for RNAi-mediated inhibition of viral replication in cell
culture (Jacque et al., 2002; ter Brake et al., 2006), and an
anti-HIV RNAi therapy is currently in clinical trials to evaluate
its safety and efficacy (Li et al., 2006; Rossi et al., 2007). How-
ever, since one or two nucleotide mismatches between the
antisense guide strand and the target RNA can disrupt RISC-
mediated cleavage (Jacque et al., 2002), HIV’s capacity for
mutation also threatens the long-term efficacy of RNAi-based
therapies (Haasnoot et al., 2007). In cell culture, HIV has already
been shown to evolve resistance to RNAi directed against tat,
gag, nef, or pol via direct point mutation of the target sequences
(Boden et al., 2003; Das et al., 2004; ter Brake et al., 2006).
Similarly, HIV evolved resistance to RNAi directed against nef
by mutating or deleting the target, which is dispensable in cell
culture (Das et al., 2004), or by a local structural rearrangement
of the target mRNA that likely results in the exclusion of RISC
(Westerhout et al., 2005). It has been proposed that directing
RNAi against HIV sequences that cannot be mutated without
compromising viral functionality may preclude viral escape.
While highly conserved sites within HIV transcripts have been
targeted (Lee et al., 2005; ter Brake et al., 2006), escape from
RNAi directed against these targets has still occurred in
10–20 days (ter Brake et al., 2006; von Eije et al., 2008).
Combinations of shRNAs may also suppress viral replication
for extended periods without escape (ter Brake et al., 2006).
In practice, however, this combinatorial RNAi approach hasvier Inc.
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avoid inducing interferon-mediated responses (Reynolds
et al., 2006), and ineffective siRNAs can compete with effective
ones for incorporation into RISC and, thereby, decrease overall
RNAi efficacy (Castanotto et al., 2007). Alternatively, RNAi may
be coupled with other RNA-based strategies to enhance sup-
pression (Li et al., 2005). However, in all cases, RNAi targets
must be selected carefully to both maximize inhibition and
prevent viral escape.
One attractive RNAi target is the trans-activation response
(TAR) hairpin, an untranslated and highly structured sequence
that is present in every viral RNA and is characterized by a high
degree of nucleotide sequence conservation resulting from the
indispensable role that TAR plays in viral transcription. Briefly, fol-
lowing reverse transcription and semirandom integration into
a host cell chromosome (Schroder et al., 2002), transcription of
all viral RNA from an HIV provirus is driven by the 50 long terminal
repeat (LTR). Initially, basal transcription is relatively inefficient
and isgovernedbycellular transcription factors throughabalance
of positive and negative regulators that bind to cis regulatory el-
ements within the 50 LTR (Imai and Okamoto, 2006; Kato et al.,
1991; Margolis et al., 1994; Nabel and Baltimore, 1987). Although
this basal transcription is relatively inefficient, it leads to the accu-
mulation of the HIV transcriptional transactivator, Tat. Tat binds
to the ‘‘bulge’’ of TAR (Roy et al., 1990), which is present at the
50 end of every nascent viral RNA transcript, and recruits the cel-
lular factors cyclin T1 and cyclin-dependent kinase 9 (CDK9)
(Zhou et al., 1998) to lead to a greatly increased viral RNA tran-
scription rate (Feinberg et al., 1991). The resulting Tat/TAR-pos-
itive feedback loop is essential for producing the viral regulatory
and structural proteins and genomic RNA required for assem-
bling progeny virions (Sodroski et al., 1986). Furthermore, the
TAR hairpin is present at both the 50 and 30 ends of both spliced
and full-length HIV transcripts, such that every HIV RNAmolecule
contains two copies of this potential RNAi target.
Previous efforts to inhibit HIV with RNAi directed against TAR
have been met with mixed success. It was reported that TAR’s
extensive secondary structure precluded cleavage by RISC
(Yoshinari et al., 2004); however, recently, it was shown that
RISC is able to efficiently cleave imperfect hairpins resembling
TAR, given the appropriate selection of an antisense guide
strand (Ameres et al., 2007), and some inhibition of HIV replica-
tion was observed using transient transfection of anti-TAR
siRNAs in cell culture (Jacque et al., 2002). However, it is
unknown whether a sustained induction of RNAi against TAR,
such as would be required for therapeutic applications, can
suppress HIV replication.
We have identified an RNAi target within TAR and shown that
viral replication is efficiently blocked in cells constitutively
expressing shRNAs targeting this sequence. However, by using
high initial viral loads or including unprotected cells (i.e., cells not
expressing an shRNA) in the cultures, some persistent viral rep-
lication could be maintained, and under several such conditions,
some viral populations rebounded in a stochastic manner.
However, when these viral strains that ‘‘evaded’’ RNAi were
sequenced and characterized, not one contained mutations in
the RNAi-targeted region of TAR or was predicted to significantly
alter RNA secondary structure in a way that would make it less
susceptible to RNAi, indicating that resistance to RNAi was notCell Hostacquired via previously described mechanisms. Instead, HIV
accumulated promoter mutations and sequence duplications
that appeared to compensate for RNAi-mediated inhibition,
rather than escape it outright, by upregulating viral gene
transcription. Thus, this viral evolution represents an indirect
response to inhibition by RNAi.
RESULTS
An Anti-TAR shRNA Conferring Long-Term Suppression
of HIV Replication
To identify sequences within TAR susceptible to RNAi-
mediated inhibition, we first tested four shRNAs targeting three
different regions within TAR for their ability to inhibit HIV gene ex-
pression (Figures 1A and 1B). TAR1 and TAR3 were based on
a single siRNA reported to have moderate success in suppress-
ing short-term viral replication (Jacque et al., 2002), and the
others targeted new sequences within TAR (Table S1 available
online). When shRNA-encoding plasmids were transiently trans-
fected (>90% transfection efficiency) into HEK293T cells ex-
pressing the green fluorescent protein (GFP) from the HIV LTR
(LGIT) (such that each mRNA contains TAR hairpins at both the
50 and 30 ends), TAR4 shRNA reduced GFP expression to an ex-
tent comparable to the potent anti-GFP control (Leirdal and
Sioud, 2002) 3 days posttransfection (Figure 1C). By contrast,
TAR4 shRNAdid not inhibit GFP expression in HEK293T cells ex-
pressing GFP from a murine retroviral vector (CLPIT
GFP), indicating its specificity. GFP levels decreased between
1 and 4 days posttransfection; however, no additional knock-
down was observed 5 days posttransfection (data not shown).
It has been reported that TAR can be processed by Dicer and
may act as amiRNA (Klase et al., 2007). To clarify themechanism
of gene knockdown, we also measured gene expression in the
presence of a TAR4 shRNA with two central mismatches at
nucleotides 9 and 10 (TAR4mm), which would be predicted to
abrogate RNAi-mediated cleavage of a target (Yu et al., 2002),
but not necessarily miRNA inhibition (Hutvagner and Zamore,
2002). The mismatched shRNA showed no significant knock-
down in the LGIT cell line, which indicates that exact sequence
identity is required for knockdown and supports an RNAi
mechanism.
To test whether the TAR4 shRNA could suppress HIV replica-
tion, we constructed a stable SupT1 human T cell line that con-
stitutively expresses this shRNA. These cells were infected with
a ‘‘triple-deletion’’ strain of HIV pNL4-3, which contains deletions
(in vpu, nef, and part of the U3 region) that do not impair replica-
tion in cell culture but enhance safety considerations (Deacon
et al., 1995; Du et al., 1993). Unprotected SupT1 cells were
also included in some cultures at several relative proportions
to assess the impact that nonsuppressive cells may have on viral
replication and evolution. Eight replicates of each condition were
used, as viral mutation and escape are stochastic processes.
Cells were initially challenged at a ratio of infectious virus to cells
(multiplicity of infection [MOI]) of 0.015. This MOI was selected to
induce robust viral replication in unprotected cells over an 8 day
period, as higher MOIs rapidly killed cells and actually reduced
the endpoint viral titer (Figure S2). For long-term culturing, viral
supernatant was transferred to fresh cell cultures (containing
proportions of protected and unprotected cells matching the& Microbe 4, 484–494, November 13, 2008 ª2008 Elsevier Inc. 485
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death of infected cells and the expansion of surviving cells. Viral
titers were tracked using an indicator cell line (CEM GFP) that
measures active viruses rather than the accumulation of viral
proteins (Gervaix et al., 1997). Briefly, the indicator cells contain
an integrated copy of the HIV LTR followed by GFP. In the
presence of Tat, supplied by HIV infection, these cells express
GFP and can be measured via flow cytometry to determine the
infectious titer (Berthoux et al., 1999; Schumacher et al., 2008)
(Figure S3).
While viral replication in unprotected cells was robust,
cultures containing protected cells showed considerably lower
titers when first measured 8 days postinfection (dpi). This sup-
pression of viral replication led some populations to become
‘‘extinct’’ with undetectable active virus (data not shown).
Despite this initial suppression, several cultures proceeded to
rebound to high viral titers in the following 24 days (Figure 2A).
The recovered viral populations were then cultured in the pres-
ence of purely protected cells for up to 18 days, allowing for the
enrichment of adaptive mutations in these populations. The
recovery of efficient viral replication was highly stochastic,
such that cultures of identical initial cellular composition either
eventually supported replication or extinguished the infection.
However, the probability of recovering efficient replication was
a strong function of the fraction of the cell population that was
unprotected (Figure 2B). More specifically, in wells containing
only protected cells, virus was extinguished in seven out of eight
wells. However, consistent with our previous computational
predictions (Leonard and Schaffer, 2005), less-protected cul-
tures were much more likely to support viral replication, and
Figure 1. Identification of Potent RNAi
Targets in the HIV TAR Element
(A) Secondary structure of HIV TAR RNA.
(B) shRNA target sequences with corresponding
TAR nucleotide (nt) positions indicated in paren-
theses. *The initial G of TAR3 is not present in
TAR.
(C) Cells expressingGFP from either the HIV (LGIT)
or murine retrovirus (CLPIT-GFP) LTR were tran-
siently transfected with U6-shRNA expression
plasmids (1.5 mg per 1 3 105 cells) and, after
3 days, mean fluorescence intensity (MFI) was
quantified by flow cytometry (Figure S1) and nor-
malized to an anti-lacZ shRNA-transfected control
(LGIT lacZ MFI = 83.4, CLPIT GFP lacZ MFI =
40.9). Experiments were performed in biological
triplicate and are representative of at least four
independent experiments. Error bars indicate
one standard deviation, and asterisks indicate
a significantly different MFI as compared to the
LacZ-negative control in the same cell type
(p < 0.05).
a relatively sharp viral replication
‘‘threshold’’ appeared as the percent of
unprotected cells reached 20%. Thus,
even though evasion of RNAi is a sto-
chastic process, key parameters (such
as the fraction of the population that is
unprotected) govern the likelihood that viral replication will
recover.
HIV Evades Anti-TAR RNAi by an Indirect Compensatory
Mechanism
We next sought to determine whether viral populations had
rebounded due to mutational adaptation. To date, viral escape
from RNAi has been found to occur only by mutation in the
targeted site or in nearby regions that modulate RNA folding at
the targeted sequence (Boden et al., 2003; Das et al., 2004; Gitlin
et al., 2005; ter Brake et al., 2006; Westerhout et al., 2005). In-
triguingly, sequence analysis of the LTRs of putative escape viral
populations revealed no mutations in the RNAi target sequence
within TAR that would be expected to alleviate RNAi-mediated
suppression. Many mutations were instead present within or ad-
jacent to transcription factor binding sites in the LTR, including
NFkB, Sp1, UBP/LBP, AP-1, and NFAT (Figure 3). Although
four separate point mutations were observed in TAR, they
occurred outside of the RNAi target sequence. Two mutations
(20D6 and 30G5) were adjacent to and within the 50 side of the
bulge responsible for Tat binding (nucleotides 23–25 in
Figure 1A) (Roy et al., 1990), and two others (10A8 and 20H4)
occurred at the base of the TAR hairpin. Only mutant 20D6
was predicted to change the secondary structure adjacent to
the RNAi target sequence, according to the mFold algorithm
(Zuker, 2003), but in a manner not likely to decrease accessibility
of the target region to RISC, as was the case in a previously
reported mechanism of HIV escape from RNAi (Westerhout
et al., 2005) since the mutation in 20D6 creates a ‘‘window’’ of
accessibility for target recognition (Ameres et al., 2007; Gredell486 Cell Host & Microbe 4, 484–494, November 13, 2008 ª2008 Elsevier Inc.
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structure and, therefore, accessibility of the target sequence
itself (Figure S5). Only one mutant expanded to dominate its viral
population (culture 20H), and many viruses isolated from other
cultures possessed the wild-type (WT) sequence in the region
analyzed (Table S2). Collectively, these data suggest that the
virus did not directly escape anti-TAR RNAi but, instead, accu-
mulated alterations in both positive and negative regulatory
elements that potentially enhance viral replication in the pres-
ence of the RNAi inhibition. In addition, the sequencing results
suggest that WT virus expansion in unprotected cells may
have contributed to the recovery of viral replication.
Fourteen mutants were selected for further analysis, based on
several criteria. First, because several regions of documented
importance were mutated in multiple variants, these variants
were selected for analysis. These included mutations in the
NFkB elements (variants 10A3 and 30A5), Sp1 elements (20D5,
Figure 2. Recovery of HIV Replication in Anti-TAR RNAi Cells
(A) TAR4 shRNA-expressing and unprotected SupT1 cells were mixed at
a range of ratios denoted by the percentage of unprotected cells (0–30, eight
replicates—A through H—of each ratio) and challenged with HIV at an MOI of
0.015. Every 8 days, supernatant was transferred to fresh cells, and infectious
titers were calculated. Viral populations that went extinct are not shown.
(B) The fraction of cultures in which the virus population went extinct, within
each group of replicates having a given ratio of protected to unprotected cells,
was determined at each time point.Cell Host20H4, 20H5, 20H15, 30A6, and 30G4), and adjacent to the
TATA box (30G8). In addition, a set of variants whose mutation
occurred within the R region of the LTR were chosen (10A6,
20D6, and 30G5), given their proximity to the RNAi-targeted
region. Mutants (0H2 and 0H16) were also chosen to represent
isolates from the various culture compositions (0%, 10%,
20%, and 30% unprotected). To prepare genetically uniform
stocks of eachmutant, we developed and utilized a viral genomic
plasmid containing a single LTR, analogous to a system devel-
oped previously (Leonard et al., 1989), to simplify genetic manip-
ulation of the LTR and viral production (Figure S6).
Using the resultingmutant viral stocks, homogeneous cultures
of either protected or unprotected cells were infected at an MOI
of 0.015. Over a 10 day period, 9 of the 14 mutants showed
significantly enhanced replication in protected cells compared
to WT virus (Figures 4A and S7). However, the replication of
these mutants in protected cells was delayed compared to their
expansion in unprotected cells, indicating that they are still sus-
ceptible to RNAi-mediated inhibition. Interestingly, six of the nine
mutants with enhanced replication in protected cells (0H2, 20D6,
20H5, 20H15, 10A3, and 30G8) also exhibited faster than WT
replication in unprotected cells. This resulted in an earlier peak
in titer for three of these six mutants (relative to the WT virus
peak) and a significantly accelerated decay in viral titer for all
six mutants. This rapid decay can be explained by accelerated
syncytia formation and cell death, as observed by light and fluo-
rescence microscopy (Figure S8). Since premature cell death
may limit the number of progeny virions produced, it is likely
that thesemutants are less fit for replication in unprotected cells.
To quantitatively compare the ability of mutant and wild-type
virus to produce progeny, we summed or integrated the infec-
tious viral titers measured every 2 days over a 10 day period
(the half-life of infectious virus is 8 hr [Perelson et al., 1996]),
such that the result was a measure of viral ‘‘burst size’’ over
the time course of the experiment (Figure 4B). The nine variants
with enhanced replication kinetics also yielded significantly
larger burst sizes in protected cells than did WT virus, indicating
that they are evading RNAi. Intriguingly, several mutants with the
largest burst sizes in protected cells also had significantly de-
creased burst sizes in unprotected cells, compared to WT virus.
Thus, these mutants apparently gained the ability to replicate in
protected cells at the cost of reduced replication in unprotected
cells, indicating that the acquired genetic changes can result in
a fitness loss in some contexts.
Next, we tested whether the nine RNAi-evading mutants
possessed altered transcriptional activity that may compensate
for RNAi-mediated inhibition (Figure 5A). First, basal LTR-driven
transcription was measured in unprotected cells by QPCR of
GFP mRNA. All mutants except mutant 20D6 exhibited higher
basal activities when measured as the RNA level. Since Tat-
transactivated transcription is essential for viral replication, we
also measured LTR activities in the presence of Tat. Mutants
0H2, 10A3, 20H5, 20H15, 30A6, and 30G8 had enhanced
transcription in the presence of Tat compared to the WT LTR
with Tat. Interestingly, mutant 20D6 appears to be virtually unre-
sponsive to Tat. A luciferase assay confirmed these trends
(Figure S9). Collectively, these results suggest that HIV acquired
the ability to replicate in RNAi-protected cells through indirect
compensatory mutations that increase the basal and/or& Microbe 4, 484–494, November 13, 2008 ª2008 Elsevier Inc. 487
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RISC-mediated downregulation of gene expression.
Since many of these mutants appeared to be evading RNAi at
the transcriptional level, we next measured the production of ini-
tiated versus fully elongated transcripts for each mutant using
a previously developedmethod (Williams et al., 2006) (Figure 5B).
All mutants produced more initiated transcripts than WT virus in
the absence of Tat. In addition, mutants 0H2, 10A3, and 20H15
exhibited enhanced initiation in the presence of Tat. Both of
these scenarios suggest that elongation has become more
efficient for these mutants in the absence and, perhaps, even
the presence of Tat. In contrast, mutant 20D6 showed an in-
crease in initiated transcription in the absence of Tat, while fully
elongated transcriptionwas not enhanced compared toWT in ei-
ther situation. This implies that a large number of transcripts are
truncated for mutant 20D6.
Combinatorial Therapies for Enhanced Antiviral Activity
Since our mutants appear to evade RNAi by a general increase in
gene expression, we investigated whether enhanced suppres-
sion ofmutant viral replication could be achieved by using a com-
bination of RNAi and a small molecule HIV inhibitor. One such
combination strategy has demonstrated improved inhibition of
both WT and drug-resistant HIV; however, in this study, the
siRNA and the small molecule antiviral targeted RT mRNA and
protein, respectively (Huelsmann et al., 2006). We analyzed
whether targeting different viral loci simultaneously, in a manner
similar to HAART, may also enhance viral inhibition. In particular,
we measured viral replication in TAR4-protected and -unpro-
tected SupT1 cells cultured with the nucleoside RT inhibitor
(NRTI) zidovudine (AZT). Combinatorial inhibition enhanced the
viral suppression exerted by either RNAi or the NRTI alone
(Figure 6). When AZT was combined with TAR4 RNAi, complete
suppression of WT viral replication was observed over 10 days,
even at AZT concentrations that were unable to inhibit viral
replication alone. Mutant 10A3, which was able to evade RNAi,
was also able to replicate in unprotected cells in the presence
of low concentrations of AZT. However, when AZT was com-
bined with RNAi, no viral replication was observed over 10 days.
Similar trends were observed for mutants 0H2, 10A3, 20H5, and
20H15 at higher MOIs (data not shown).
DISCUSSION
Here, we describe the selection of indirect compensatory muta-
tions in HIV when its replication is inhibited by RNAi directed
Figure 3. Summary of Potential Escape Mutants
(A) Locations of LTR mutations in isolates from ‘‘escaped’’ wells are indicated by black arrows.
(B) A summary of individual mutants, with bold text indicating mutants that were selected for further analysis, is shown. Mutant names indicate where the mutant
arose (‘‘20D5’’ = isolate from a culture with 20% unprotected cells, culture replicate D, isolate number 5 from this culture). D indicates a deletion; ‘‘ins,’’ an
insertion; and ‘‘dup,’’ a duplication. Individual mutations are numbered using +1 for the transcriptional start site. Complete mutant LTR sequences are available
in Figure S4. Frequencies of each mutant are listed in Table S2.488 Cell Host & Microbe 4, 484–494, November 13, 2008 ª2008 Elsevier Inc.
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HIV Evades RNAi by a Compensatory MechanismFigure 4. Enhanced Replication of Evading Mutants
(A) TAR4-protected or -unprotected SupT1 cells were challenged with either WT virus or each potential evasion mutant at an MOI of 0.015. Mutants that did not
show enhanced replication are included in Figure S7.
(B) Total viral yield (burst size) was calculated by integrating the titers from (A) and normalizing to WT virus (in identical cells).
Experiments were performed in biological triplicate, error bars represent one standard deviation, and asterisks indicate a significantly different titer (or burst size)
as compared to WT virus replicating in the same cell type (p < 0.05).against an evolutionarily conserved target.We identified a shRNA
that targets a sequence in TAR that is highly conserved, even
between HIV-1 subtypes, and that efficiently suppresses viral
replication. However, mutants capable of evading RNAi emerged
in long-term culture, particularly in mixtures of RNAi-protected
and -unprotected cells. Interestingly, no variants escaped the
RNAi directly, but the virus instead upregulated its gene expres-
sion to compensate for this inhibition. Importantly, these results
reveal that HIV can adaptively tune its gene regulation to enable
viral evasion.Cell HostExisting HAART drugs interfere with viral replication via bind-
ing directly to target HIV proteins and inhibiting their function
by either competing for catalytic sites or blocking conformational
changes required for activity. Consequently, mutations affecting
the targeted proteins may alter the physical interactions with
antiviral drugs and, thereby, allow these proteins to function in
the presence of the associated inhibitors. While viral resistance
mutations may initially impair the function of these proteins,
additional compensatory mutations affecting the targeted pro-
tein (or other viral proteins) can restore overall viral fitness. For& Microbe 4, 484–494, November 13, 2008 ª2008 Elsevier Inc. 489
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HIV Evades RNAi by a Compensatory MechanismFigure 5. Transcriptional Activity of Mutant LTRs
Tat-expressing or naive SupT1 cells were transduced with vectors expressing GFP and luciferase from either WT or evading mutant HIV LTRs at MOIs of 1.5.
(A) Basal and transactivated transcription rates of each mutant were measured by QPCR of GFPmRNA using the DDCTmethod (Livak and Schmittgen, 2001). All
values were normalized for amplification efficiency.
(B) The number of initiated and fully elongated transcripts was measured using QPCR as above. All values were normalized for amplification efficiency. The
difference between these two values is considered the number of truncated transcripts (Williams et al., 2006).
Experiments were performed in technical triplicate. Error bars represent one standard deviation, and asterisks indicate a statistically different value than therespective WT value (p < 0.05).example, mutations altering HIV protease result in virus that is
resistant to Protease inhibitors, and compensatory mutations
altering Protease’s viral substrate, Gag, restore viral fitness
(reviewed in Clavel andHance [2004]). However, in all such cases
of resistance to existing HIV therapies, the underlying mutations
occur exclusively within the protein-coding sequences affected
by the therapy. Likewise, in all cases of evolved resistance to
RNAi described to date, viruses have acquired point mutations
or deletions in the target sequence (Boden et al., 2003; Das
et al., 2004; Gitlin et al., 2005; ter Brake et al., 2006; Wilson and
Richardson, 2005; Wu et al., 2005) or have structurally arranged
the target sequence to render it inaccessible to RISC (Westerh-
out et al., 2005). In each case, resistance was conferred by a
direct alleviation of RNAi-mediated inhibition.
We describe an alternate pathway of viral evolution in
response to RNAi. No direct escape from RNAi occurred, pre-
sumably because TAR is essential for replication, and neither
the primary RNA sequence nor secondary structure can bemod-490 Cell Host & Microbe 4, 484–494, November 13, 2008 ª2008 Elsified without severely compromising viral function (Selby et al.,
1989). Instead, we identified variants harboring mutations within
the HIV LTR promoter that confer the ability to replicate in the
presence of the anti-TAR shRNA. However, all mutants continue
to be partially inhibited by this RNAi. Several mutants (0H2, 10A3,
20D5, and 20H5 and 20H15, 30A5, 30A6, and 30G8) acquired
increased basal or Tat-transactivated transcription rates relative
to the WT promoter, suggesting that they persisted by over-
whelming the RNAi machinery with viral transcripts. Thus,
when RNAi is directed against a highly conserved viral target,
such as TAR, the result is viral evolution based on modulation
of genetic elements that regulate overall levels of viral gene ex-
pression. Interestingly, the concept that viruses can overwhelm
endogenous pathways has some parallels in protein translation
in adenovirus biology (Mathews and Shenk, 1991), and bacterial
pathogens, such as Mycobacterium tuberculosis, are known to
evolve drug resistance conferred by a promoter mutation (Rinder
et al., 1998).evier Inc.
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HIV Evades RNAi by a Compensatory MechanismFigure 6. Combinatorial Inhibition of HIV with Anti-TAR RNAi and Antiviral Drugs
TAR4-protected or -unprotected SupT1s were infected withWT or mutant 10A3 virus at anMOI of 0.015 in the presence of AZT. Titers were assayed every 2 days
for 10 days. Experiments were performed in biological triplicate. Error bars represent one standard deviation, and asterisks indicate statistically significant titer as
compared to WT virus replicating in the same cell type (p < 0.05).An examination of the mutations that conferred enhanced viral
replication suggests several possible mechanisms by which HIV
may modulate its genetic regulation. One class of mutations oc-
curred in sites that can either enhance or suppress gene expres-
sion. The HIV LTR contains two NFkB binding sites. In mutants
10A3 and 30A5, NFkB site II was mutated to sequences shown
to impair binding of the repressive homodimer (Wang et al.,
2003), which may tip the regulatory scales in favor of transcrip-
tion. The LTR also contains binding sites for Sp1, which again
recruits both positive (p300) and negative (HDACs) regulators
(Doetzlhofer et al., 1999; Suzuki et al., 2000). Mutants 20H5
and 20H15 contain tandem Sp1 site duplications, apparently
acquired through sequential recombination events during viral
replication. While p300-bound Sp1 is known to have a reduced
affinity for DNA relative to Sp1 or HDAC-bound Sp1 (Suzuki
et al., 2000), the co-operative nature of Sp1 binding to DNA
(Mastrangelo et al., 1991) may again push the balance toward
activation of transcription.
It should be noted that this type of duplication of Sp1 binding
sites has been observed during the long-term passage of the tri-
ple-deletion HIV strain used in this study (Berkhout et al., 1999).
Therefore, we sought to address the possibility that this mutation
is a consequence of in vitro culturing of attenuated HIV. We con-
firmed that, in the full-length HIV-1 strain NL4-3, the Sp1 duplica-
tion mutant (20H5) confers a significant replication advantage
compared to WT virus in protected cells (Figure S10). Further-
more, the inclusion of this mutation in the full-length strain results
in accelerated replication kinetics in unprotected cells and
a lower total burst size over 10 days compared to the WT virus
(Figure S10). While the differences in replication are less pro-
nounced in the full-length strain, the phenotypes are consistent
with results using the triple-deletion strain. This finding supports
the interpretation that the observed Sp1 duplications are an
adaptation that helps HIV to overcome both RNAi-mediated
pressure and attenuation by gene deletion, since this adaptive
advantage can be observed in both the wild-type and attenuated
HIV strains used in this study.
The observed increase in initiated transcription in a number of
mutants in the absence of Tat, coupled with enhanced basalCell Hostelongation rates, suggests that some mutants may ‘‘jump start’’
viral gene expression by producing a large number of initiated
transcripts. Notably, none of the observed mutations were pre-
dicted to alter the structure of the TAR hairpin in a substantial
manner, suggesting that target accessibility to RISC should not
be decreased. However, mutant 20D6 contains a mutation
below the Tat-binding bulge, which may increase the size of
the bulge, as predicted by Mfold. This mutant exhibited reduced
initiation and basal transcription rates, and it remains unrespon-
sive to Tat, suggesting that the larger bulge may affect Tat
binding and transactivation. Additionally, the large difference in
initiated versus elongated transcripts produced by this mutant
suggests that truncated transcripts may also serve as decoys
that saturate TAR4-loaded RISC machinery. Finally, seemingly
nonadaptive mutants (and apparently WT virus) may have prop-
agated through coupled replication with adaptive variants, and it
remains possible that some variants possessed adaptive muta-
tions outside of the analyzed region.
We have shown that RNAi directed against TAR can inhibit HIV
replication; however, viral evasion occurred via indirect mecha-
nisms involving compensatory upregulation of gene expression.
It remains to be seen whether similar behavior exists in vivo, but
our results combining inhibitory RNAi with antiviral drugs sug-
gest a strategy for suppressing replication and, correspondingly,
viral escape. In summary, evolutionary tuning of viral gene
regulation may represent a general mechanism by which viruses
adapt to selective pressure and escape antiviral therapy.
EXPERIMENTAL PROCEDURES
Cell Culture
HEK293T cells (ATCC) were cultured in IMDM (Mediatech) with 10% FBS
(GIBCO) and 100 U/ml penicillin + 100 mg/ml streptomycin (GIBCO). SupT1
cells and CEM GFP cells, obtained via the NIH AIDS Research and Reference
Reagent Program, were cultured in RPMI (Mediatech) containing 10% FBS
and antibiotics as above.
RNAi Expression Constructs
RNAi-inducing cassettes using the human U6 promoter from pTZU6+1
(Scherer et al., 2004) were constructed by PCR (Table S1). Targets in GFP& Microbe 4, 484–494, November 13, 2008 ª2008 Elsevier Inc. 491
Cell Host & Microbe
HIV Evades RNAi by a Compensatory Mechanism(Leirdal and Sioud, 2002) and LacZ (Qin et al., 2003) were previously de-
scribed. U6-shRNA cassettes were inserted into pBS SK+ (Stratagene) for
transient expression. The U6-TAR4 cassette was subcloned into the self-
inactivating lentiviral vector pHIV CS (Miyoshi et al., 1998), and a CMV-NeoR
selection cassette from pcDNA3.1 (Invitrogen) was inserted upstream of the
30 LTR to generate a vector for inducing sustained TAR4 shRNA expression.
Cell Line Generation
For stable GFP expression, the lentiviral vector LGIT and the murine retroviral
vector CLPIT-GFP were packaged as previously described (Yu and Schaffer,
2006). HEK293 cells were infected with LGIT at an MOI of 1 and with CLPIT-
GFP at an MOI = 0.1, followed by selection in 1 mg/ml puromycin (Sigma-
Aldrich). SupT1 cells were infected with TAR4 shRNA lentiviral vectors
(produced as above) at an MOI of 0.1, and cells were selected with 500 mg/ml
G418 sulfate (Invitrogen).
HIV Stock Preparation and Titering
WT HIV stocks were generated from the hemigenomic plasmids p210-19 and
p210-8 (NIH AIDSProgram) as described (Gibbs et al., 1994). Individualmutant
viruses were produced using a single-LTR packaging platform (psLTR HIV)
(Figure S6), which was generated by combining p210-19 and p210-8. Muta-
tions were introduced into psLTR HIV by QuikChange PCR (Stratagene)
(primer sequences available upon request), and each mutant LTR was se-
quenced and subcloned back into the parental plasmid to avoid unintended
mutations. Full-length HIV was generated by combining hemigenomic
plasmids p83-2 and p83-10 (NIH AIDS Program). To generate mutant and
full-length HIV stocks, HEK293Ts were transfected with psLTR templates
and helper plasmids (pcDNA3 IVS VSV-G, pMDLg/pRRE, pRSV Rev, and
pCLPIT-tat mCherry) to increase packaging efficiency. The resulting virus
was amplified on SupT1s and titered on CEM GFP indicator cells (Gervaix
et al., 1997). To titer virus, 100–300 ml of viral supernatant was used to infect
1 3 105 CEM GFP cells using 2 mg/ml polybrene (American Bioanalytical)
and 0.1 mM saquinivir (NIH AIDS Program). After 3 days, CEM GFP cells
were fixed in 2% paraformaldehyde, and transduction efficiency was as-
sessed by flow cytometry (Figure S3) and used to calculate viral titer.
HIV Propagation Experiments
43 105 TAR4-protected and -unprotected SupT1s were mixed as indicated in
1.5 ml of medium and infected with HIV at an MOI of 0.015. At 2 day intervals,
700 ml of medium was removed for titering and replaced with fresh medium.
For long-term experiments, every eighth day, 250 ml of supernatant was trans-
ferred to a new culture of 43 105 cells (matching the initial composition of the
cell population). Potentially resistant cultures were isolated at 32 dpi, enriched
on RNAi-protected cells for up to 18 days, and titered on CEM GFP cells.
Cellular genomic DNA was also harvested from these cells as previously de-
scribed (Delassus et al., 1991; Meyerhans et al., 1989), and 50 LTR sequences
were recovered by PCR (primer sequences available upon request) and
inserted in pBS SK+ for sequencing.
LTR Transcription Assays
A lentiviral vector (LLIG) was created by modifying LGIT to place a luciferase-
IRES-GFP cassette under the transcriptional control of the HIV LTR. Mutants
were produced as above and packaged as previously described (Weinberger
et al., 2005). SupT1s were infected with LLIG variants, and Tat expression was
induced by transduction with a lentiviral vector expressing Tat from a ubiquitin
promoter. Cells were cultured for 3 weeks to allow transcription to reach
steady state, and transcriptional activity was measured by detection of GFP
mRNA using QPCR. Values were normalized for LLIG infection efficiency as
quantified by QPCR of viral stocks using GFP primers.
RNA Extraction and Quantification by QPCR
Total RNA from SupT1 cells was isolated using Trizol (Invitrogen), and
transcripts were quantified using the QuantiTect SYBR Green RT-PCR kit
(QIAGEN) on the Bio-Rad iCycler with the DDCT method (Livak and Schmitt-
gen, 2001). Initiated transcripts were detected with TAR primers HIVTAR5
(50-GTTAGACCAGATCTGAGCCT-30) and HIVTAR3 (50-GTGGGTTCCCTAGT
TAGCCA-30 ) (Williams et al., 2006). Elongated transcripts were detected
with GFP primers GFP5 (50- AGCAAAGACCCCAACGAGAA-30) and GFP3492 Cell Host & Microbe 4, 484–494, November 13, 2008 ª2008 Els(50- CGTCCATGCCGAGAGTGAT-30) (Weinberger et al., 2005). For each
sample, measurements were normalized by the corresponding levels of
b-Actin mRNA, which were quantified with primers b-Actin5 (50-ACCTGAC
TGACTACCTCATGAAGATCCTCACCGA-30) and b-Actin3 (50-GGAGCTGGA
AGCAGCCGTGGCCATCTCTTGCTCGAA-30) (Weinberger et al., 2005). Tripli-
cate RT-QPCRmeasurements were performed for all samples for each primer
set, and melt curves were performed on the Bio-Rad iCycler for all samples to
confirm the specificity of QPCR reaction.
Statistical Analysis
All statistical analysis was conducted using the Student’s t test with a threshold
p value of 0.05.
SUPPLEMENTAL DATA
The Supplemental Data include ten figures and two tables and can be found
with this article online at http://www.cellhostandmicrobe.com/supplemental/
S1931-3128(08)00304-1.
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